Teva Pharmaceutical Industries Ltd. — Director's Dealing 2024

Mar 5, 2024

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

(Print or Type Responses)

1. Name and Address of Reporting Person Conway Vikki L.	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (Middle) (First) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 03/03/2024	Officer (give title below) Other (specify below) See "Remarks"
(Street) Tel Aviv, L3 6944020	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) any	2A. Deemed Execution Date, if Code (Month/Day/Year)	3. Transaction (Instr. 8)		or Disposed of (D) (Instr. 3, 4 and 5)			4. Securities Acquired (A) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Form: Direct (D) Ownership	7. Nature Ownership of Indirect Beneficial
			Code		Amount	(A) Or (D)	Price		or Indirect (Instr. 4) (1) (Instr. 4)
'Ordinary Shares (1)	03/03/2024		M		5,179	A	(2)	8,107	D
'Ordinary Shares (1)	03/04/2024		દ્વ(3)		1.490 (4)	D	13.3733	6.617	D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

FORM 4

				(5)
Ordinary Shares (1)	03/04/2024	M =	7,117 A		13,734	D
Ordinary Shares (1)	03/04/2024	g(3)	2,042 (4)	. D 13.3733 (5)	11,692	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

		( e.g. , puts, calls, warrants, options, convertible securities)

					1 - 0 - 7 1 - - - 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
1. Title of Derivative Security (Instr. 3)	2. Conversion Date Price of Derivative Security	3. Transaction or Exercise (Month/Day/Year) any	3A. Deemed Execution Date, if Transaction Derivative (Month/Day/Year) (Instr. 8)	4. Code	5. Number of Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and ર)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Security (Instr. 5)	8. Price of 9. Number of Derivative Derivative Securities Beneficially Owned Following Reported	10. Form of Derivative Security: Direct (D) or Indirect	11. Nature Ownership of Indirect Beneficial Ownership Instr. 4)
				Code	(A)	(D)	Date Exercisable Date	Expiration	Title	Amount 01 Number of Shares		Transaction(s) (Instr. 4)	(1) (Instr. 4)
Restricted Share Units	(2)	03/03/2024		M		5,179	(6)	(6)	Ordinary Shares (1)	5,179	\$ 0	15,538	D
Restricted Share Units	(2)	03/04/2024		M		7,117	(7)	(7)	Ordinary Shares (1)	7,117	\$ 0	14,237	D
Restricted Share Units	(2)	03/04/2024		A	33,482		(8)	(8)	Ordinary Shares (1)	33,482	\$ 0	33,482	D

Explanation of Responses:

• 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• 1. Each restricted share unit epresents at settlement, one ordinary share or, at the option of the Human Resources and Committee, the cash value of one ordinary share.
• 1. The transaction reported in this Form 4 was effected pursuant to a Rule 1065-1 trading plan adopted by the reporting person on November 21, 2023.
• 1. Represents the number of shares required to be sold by the resert as withouting collections in comection with the vesting of the resting of the resting of the resting of t
• 1. The price reported in Column 4 is a vegled in multiple transactions at prices ranging from \$1.2.5 to \$13.445, inclusive. The reportung person underskes to provide, upon request by the issuer, or any security holder of the issuer, full information regarding the number of shares solo at each sparate price.
• 1. Restricted share units were granted on March 3, 2024, March 3, 2024, March 3, 2024, March 3, 2026, and 5, 180 vesting on March 3, 2027,

• Restricted share units were granted on March 4, 2022, with 7, 17 vesting on each of March 4, 2025, and 7, 20 vesing on March 4, 2026.

• Restricted share units were granted on March 4, 2024, with 8,300 vesting on each of Mach 4, 2027, and 8,372 vesting on March 4, 2127, and 8,372 vesting on March 4, 2128.

Remarks:

Acting Head of Global Human Resources

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Vikki L. Conway 03/05/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18tf(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of inthis form are not required to respond unless the form displays a currently valid OMB Number.